Structure-based design, synthesis, and structure-activity relationship studies of HIV-1 protease inhibitors incorporating phenyloxazolidinones

Journal of Medicinal Chemistry

Volumn 53, Issue 21, 2010, Pages 7699-7708

  Ali, Akbar ^a   Reddy, G S Kiran Kumar ^a   Nalam, Madhavi N L ^a   Anjum, Saima Ghafoor ^a   Cao, Hong ^a   Schiffer, Celia A ^a   Rana, Tariq M ^a,b  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^b BURNHAM INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 (3 AMINOPHENYL) N [3 [(6 BENZOTHIAZOLYLSULFONYL)(2 METHYLPROPYL)AMINO] 2 HYDROXY 1 (PHENYLMETHYL)PROPLYL] 2 OXOOXAZOLIDINE 5 CARBOXAMIDE; ANTIVIRUS AGENT; ETHANOLAMINE DERIVATIVE; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; UNCLASSIFIED DRUG;

ARTICLE; BINDING AFFINITY; CRYSTAL STRUCTURE; DRUG DESIGN; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG SYNTHESIS; HUMAN IMMUNODEFICIENCY VIRUS 1; NONHUMAN; STRUCTURE ACTIVITY RELATION;

ANTI-HIV AGENTS; BINDING SITES; CRYSTALLOGRAPHY, X-RAY; DRUG DESIGN; DRUG RESISTANCE, MULTIPLE, VIRAL; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; MOLECULAR STRUCTURE; MUTATION; OXAZOLIDINONES; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 78149278849     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm1008743     Document Type: Article

References (42)

1. The Joint United Nations Program on HIV/AIDS (UNAIDS). 2008 Report on the Global AIDS Epidemic; UNAIDS: Geneva, Switzerland, 2008.
2. Hammer, S. M.; Eron, J. J., Jr.; Reiss, P.; Schooley, R. T.; Thompson, M. A.; Walmsley, S.; Cahn, P.; Fischl, M. A.; Gatell, J. M.; Hirsch, M. S.; Jacobsen, D. M.; Montaner, J. S. G.; Richman, D. D.; Yeni, P. G.; Volberding, P. A. Antiretroviral treatment of adult HIV infection: 2008 recommendations of the international AIDS society-USA panel JAMA, J. Am. Med. Assoc. 2008, 300, 555-570
3. Gulick, R. M.; Mellors, J. W.; Havlir, D.; Eron, J. J.; Meibohm, A.; Condra, J. H.; Valentine, F. T.; McMahon, D.; Gonzalez, C.; Jonas, L.; Emini, E. A.; Chodakewitz, J. A.; Isaacs, R.; Richman, D. D. 3-Year suppression of HIV viremia with indinavir, zidovudine, and lamivudine Ann. Intern. Med. 2000, 133, 35-39
4. Bartlett, J. A.; DeMasi, R.; Quinn, J.; Moxham, C.; Rousseau, F. Overview of the effectiveness of triple combination therapy in antiretroviral-naive HIV-1 infected adults AIDS 2001, 15, 1369-1377
5. Palella, F. J., Jr.; Delaney, K. M.; Moorman, A. C.; Loveless, M. O.; Fuhrer, J.; Satten, G. A.; Aschman, D. J.; Holmberg, S. D.; HIV Outpatient Study Investigators. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection N. Engl. J. Med. 1998, 338, 853-860
6. Hogg, R. S.; Heath, K. V.; Yip, B.; Craib, K. J. P.; O'Shaughnessy, M. V.; Schechter, M. T.; Montaner, J. S. G. Improved survival among HIV-infected individuals following initiation of antiretroviral therapy JAMA, J. Am. Med. Assoc. 1998, 279, 450-454
7. Mehellou, Y.; De Clercq, E. Twenty-six years of anti-HIV drug discovery: where do we stand and where do we go? J. Med. Chem. 2010, 53, 521-538
8. Kempf, D. J.; Marsh, K. C.; Kumar, G.; Rodrigues, A. D.; Denissen, J. F.; McDonald, E.; Kukulka, M. J.; Hsu, A.; Granneman, G. R.; Baroldi, P. A.; Sun, E.; Pizzuti, D.; Plattner, J. J.; Norbeck, D. W.; Leonard, J. M. Pharmacokinetic enhancement of inhibitors of the human immunodeficiency virus protease by coadministration with ritonavir Antimicrob. Agents Chemother. 1997, 41, 654-660
9. Zeldin, R. K.; Petruschke, R. A. Pharmacological and therapeutic properties of ritonavir-boosted protease inhibitor therapy in HIV-infected patients J. Antimicrob. Chemother. 2004, 53, 4-9
10. Youle, M. Overview of boosted protease inhibitors in treatment- experienced HIV-infected patients J. Antimicrob. Chemother. 2007, 60, 1195-1205
11. Turner, S. R.; Strohbach, J. W.; Tommasi, R. A.; Aristoff, P. A.; Johnson, P. D.; Skulnick, H. I.; Dolak, L. A.; Seest, E. P.; Tomich, P. K.; Bohanon, M. J.; Horng, M. M.; Lynn, J. C.; Chong, K. T.; Hinshaw, R. R.; Watenpaugh, K. D.; Janakiraman, M. N.; Thaisrivongs, S. Tipranavir (PNU-140690): a potent, orally bioavailable nonpeptidic HIV protease inhibitor of the 5,6-dihydro-4-hydroxy-2-pyrone sulfonamide class J. Med. Chem. 1998, 41, 3467-3476
12. Koh, Y.; Nakata, H.; Maeda, K.; Ogata, H.; Bilcer, G.; Devasamudram, T.; Kincaid, J. F.; Boross, P.; Wang, Y. F.; Tie, Y.; Volarath, P.; Gaddis, L.; Harrison, R. W.; Weber, I. T.; Ghosh, A. K.; Mitsuya, H. Novel bis-tetrahydrofuranylurethane-containing nonpeptidic protease inhibitor (PI) UIC-94017 (TMC114) with potent activity against multi-PI-resistant human immunodeficiency virus in vitro Antimicrob. Agents Chemother. 2003, 47, 3123-3129
13. De Meyer, S.; Azijn, H.; Surleraux, D.; Jochmans, D.; Tahri, A.; Pauwels, R.; Wigerinck, P.; de Bethune, M. P. TMC114, a novel human immunodeficiency virus type 1 protease inhibitor active against protease inhibitor-resistant viruses, including a broad range of clinical isolates Antimicrob. Agents Chemother. 2005, 49, 2314-2321
14. Surleraux, D. L.; Tahri, A.; Verschueren, W. G.; Pille, G. M.; de Kock, H. A.; Jonckers, T. H.; Peeters, A.; De Meyer, S.; Azijn, H.; Pauwels, R.; de Bethune, M. P.; King, N. M.; Prabu-Jeyabalan, M.; Schiffer, C. A.; Wigerinck, P. B. Discovery and selection of TMC114, a next generation HIV-1 protease inhibitor J. Med. Chem. 2005, 48, 1813-1822
15. Esté, J. A.; Cihlar, T. Current status and challenges of antiretroviral research and therapy Antiviral Res. 2010, 85, 25-33
16. Clavel, F.; Hance, A. J. HIV drug resistance N. Engl. J. of Med. 2004, 350, 1023-1035
17. Baxter, J. D.; Schapiro, J. M.; Boucher, C. A. B.; Kohlbrenner, V. M.; Hall, D. B.; Scherer, J. R.; Mayers, D. L. Genotypic changes in human immunodeficiency virus type 1 protease associated with reduced susceptibility and virologic response to the protease inhibitor tipranavir J. Virol. 2006, 80, 10794-10801
18. De Meyer, S.; Vangeneugden, T.; Van Baelen, B.; De Paepe, E.; Van Marck, H.; Picchio, G.; Lefebvre, E.; De Béthune, M.-P. Resistance profile of darunavir: combined 24-week results from the POWER trials AIDS Res. Hum. Retroviruses 2008, 24, 379-388
19. Shafer, R. W.; Schaprio, J. M. HIV-1 drug resistance mutations: an updated framework for the second decade of HAART AIDS Rev. 2008, 10, 67-84
20. Ali, A.; Reddy, G. S. K. K.; Cao, H.; Anjum, S. G.; Nalam, M. N. L.; Schiffer, C. A.; Rana, T. M. Discovery of HIV-1 protease inhibitors with picomolar affinities incorporating N -aryl-oxazolidinone-5-carboxamides as novel P2 ligands J. Med. Chem. 2006, 49, 7342-7356
21. Reddy, G. S. K. K.; Ali, A.; Nalam, M. N. L.; Anjum, S. G.; Cao, H.; Nathans, R. S.; Schiffer, C. A.; Rana, T. M. Design and synthesis of HIV-1 protease inhibitors incorporating oxazolidinones as P2/P2' ligands in pseudosymmetric dipeptide isosteres J. Med. Chem. 2007, 50, 4316-4328
22. Ali, A.; Reddy, G. S. K. K.; Cao, H.; Anjum, S. G.; Nalam, M. N. L.; Schiffer, C. A.; Rana, T. M. Design, Synthesis, and Biological Evaluation of HIV-1 Protease Inhibitors Incorporating Phenyloxazolidines as Novel P2 Ligands. Presented at the National Meeting of the American Chemical Society, 2007; MEDI-094.
23. Nalam, M. N. L.; Ali, A.; Altman, M. D.; Reddy, G. S. K. K.; Chellappan, S.; Kairys, V.; Ozen, A.; Cao, H.; Gilson, M. K.; Tidor, B.; Rana, T. M.; Schiffer, C. A. Evaluating the substrate-envelope hypothesis: structural analysis of novel HIV-1 protease inhibitors designed to be robust against drug resistance J. Virol. 2010, 84, 5368-5378
24. Brickner, S. J.; Hutchinson, D. K.; Barbachyn, M. R.; Manninen, P. R.; Ulanowicz, D. A.; Garmon, S. A.; Grega, K. C.; Hendges, S. K.; Toops, D. S.; Ford, C. W.; Zurenko, G. E. Synthesis and antibacterial activity of U-100592 and U-100766, two oxazolidinone antibacterial agents for the potential treatment of multidrug-resistant Gram-positive bacterial infections J. Med. Chem. 1996, 39, 673-679
25. Altman, M. D.; Ali, A.; Reddy, G. S. K. K.; Nalam, M. N. L.; Anjum, S. G.; Cao, H.; Chellappan, S.; Kairys, V.; Fernandes, M. X.; Gilson, M. K.; Schiffer, C. A.; Rana, T. M.; Tidor, B. HIV-1 protease inhibitors from inverse design in the substrate envelope exhibit subnanomolar binding to drug-resistant variants J. Am. Chem. Soc. 2008, 130, 6099-6113
26. Freire, E. Do enthalpy and entropy distinguish first in class from best in class? Drug Discovery Today 2008, 13, 869-874
27. Bissantz, C.; Kuhn, B.; Stahl, M. A medicinal chemist's guide to molecular interactions J. Med. Chem. 2010, 53, 5061-5084
28. Matayoshi, E. D.; Wang, G. T.; Krafft, G. A.; Erickson, J. Novel fluorogenic substrates for assaying retroviral proteases by resonance energy transfer Science 1990, 247, 954-958
29. King, N. M.; Melnick, L.; Prabu-Jeyabalan, M.; Nalivaika, E. A.; Yang, S. S.; Gao, Y.; Nie, X.; Zepp, C.; Heefner, D. L.; Schiffer, C. A. Lack of synergy for inhibitors targeting a multi-drug-resistant HIV-1 protease Protein Sci. 2002, 11, 418-429
30. Greco, W. R.; Hakala, M. T. Evaluation of methods for estimating the dissociation constant of tight binding enzyme inhibitors J. Biol. Chem. 1979, 254, 12104-12109
31. Petropoulos, C. J.; Parkin, N. T.; Limoli, K. L.; Lie, Y. S.; Wrin, T.; Huang, W.; Tian, H.; Smith, D.; Winslow, G. A.; Capon, D. J.; Whitcomb, J. M. A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1 Antimicrob. Agents Chemother. 2000, 44, 920-928
32. Minor, W. XdisplayF; Purdue University: West Lafayette, IN, 1993.
33. Otwinowski, Z.; Minor, W. Processing of X-ray diffraction Data Collected in Oscillation Mode. In Methods in Enzymology; Carter, C. W., Jr.; Sweet, R. M., Eds.; Academic Press: San Diego, CA, 1997; Vol. 276, pp 307 - 326.
34. Collaborative Computational Project, Number 4. The CCP4 suite: programs for protein crystallography. Acta Crystallogr. 1994, D50, 760 - 763.
35. Navaza, J. AMoRe: an automated package for molecular replacement Acta Crystallogr. 1994, A50, 157-163
36. Prabu-Jeyabalan, M.; Nalivaika, E.; Schiffer, C. A. How does a symmetric dimer recognize an asymmetric substrate? A substrate complex of HIV-1 protease J. Mol. Biol. 2000, 301, 1207-1220
37. Morris, R. J.; Perrakis, A.; Lamzin, V. S. ARP/wARP's model-building algorithms. I. The main chain Acta Crystallogr. 2002, D58, 968-975
38. Emsley, P.; Cowtan, K. Coot: model-building tools for molecular graphics Acta Crystallogr. 2004, D60, 2126-2132
39. Murshudov, G. N.; Vagin, A. A.; Dodson, E. J. Refinement of macromolecular structures by the maximum-likelihood method Acta Crystallogr. 1997, D53, 240-255
40. Schomaker, V.; Trueblood, K. N. On the rigid-body motion of molecules in crystals Acta Crystallogr. 1968, B24, 63-76
41. Kuriyan, J.; Weis, W. I. Rigid protein motion as a model for crystallographic temperature factors Proc. Natl. Acad. Sci. U.S.A. 1991, 88, 2773-2777
42. Tickle, I. J.; Moss, D. S. Modeling Rigid-Body Thermal Motion in Macromolecular Crystal Structure Refinement. In IUCr99 Computing School; IUCr: London, 1999.